TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22403977

Group type: EXPERIMENTAL
Intervention: Alcohol-free mouthwash containing 0.075% CPC and 0.05% NaF
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control mouthwash containing only 0.05% NaF
Number of subjects: 110
Study: 17624606

Group type: EXPERIMENTAL
Intervention: Home-based exercise (HBE) rehabilitation group, n = 16
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual care group (UC), n = 11
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study: 16631000

Group type: EXPERIMENTAL
Intervention: Tac
Number of subjects: 44

Group type: COMPARATOR
Intervention: CyA
Number of subjects: 44
Study: 14598509

Group type: EXPERIMENTAL
Intervention: Segment resection + axillar dissection + radiotherapy
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Petey-Dyson mastectomy
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: Hormone therapy by progestagens and antiestrogens
Number of subjects: 1083
Study: 11304054

Group type: EXPERIMENTAL
Intervention: CHIK vaccine
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 8652317

Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.3% ropivacaine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 36
Study: 1999706

Group type: EXPERIMENTAL
Intervention: MTX 200 mg/m2 followed by 5-FU 600 mg/m2 (arm A)
Number of subjects: 168

Group type: COMPARATOR
Intervention: MTX 200 mg/m2 followed by 5-FU 600 mg/m2 (arm B)
Number of subjects: 168
Study: 6095656

Group type: EXPERIMENTAL
Intervention: H2-receptor antagonists (ranitidine and cimetidine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine and cimetidine
Number of subjects: 0
Study: 31778471

Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer restorations (ART/HVGIC)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional resin composite restorations (CRT)
Number of subjects: 66
Study: 28771864

Group type: EXPERIMENTAL
Intervention: Spine Care for Nurses programme (3 months duration)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (brief written lifestyle guidance)
Number of subjects: 137
Study: 27142078

Group type: EXPERIMENTAL
Intervention: Twice daily assisted exercise intervention (n = 13)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Once daily assisted exercise intervention (n = 11)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No intervention (control, n = 10)
Number of subjects: 34
Study: 25315942

Group type: EXPERIMENTAL
Intervention: Esmolol (beta-blocker)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 41
Study: 21861845

Group type: EXPERIMENTAL
Intervention: ARB therapy (losartan, 100 mg/day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 53
Study: 20653945

Group type: EXPERIMENTAL
Intervention: Diesel exhaust exposure (approximately 250 microg/m3) during intermittent exercise for one hour
Number of subjects: 18

Group type: COMPARATOR
Intervention: Filtered air exposure during intermittent exercise for one hour
Number of subjects: 18
Study: 17439735

Group type: EXPERIMENTAL
Intervention: Splenic auto‐transplantation and oesophageal transection anastomosis
Number of subjects: 274

Group type: COMPARATOR
Intervention: Splenic auto‐transplantation
Number of subjects: 274
Study: 16295811

Group type: EXPERIMENTAL
Intervention: Automatic transport ventilator (ATV)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Bag valve (BV)
Number of subjects: 28
Study: 12073199

Group type: EXPERIMENTAL
Intervention: Diltiazem (bolus 0.25 mg/kg followed by continuous infusion of 1.7 microg/kg/min) (DTZ, n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (C, n = 12)
Number of subjects: 24
Study: 9799972

Group type: EXPERIMENTAL
Intervention: Red ginseng (4.5 g/day)
Number of subjects: 34
Study: 7701397

Group type: EXPERIMENTAL
Intervention: Pedicle screw/plate system
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-instrumented control (literature controls)
Number of subjects: 28
Study: 2649743

Group type: EXPERIMENTAL
Intervention: LPS (20 u/kg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Burn patients (10-70% body surface area)
Number of subjects: 49
Study: 401853

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tobramycin (for gram-negative bacilli infections)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amikacin (for gram-negative bacilli infections)
Number of subjects: 0
Study: 29172739

Group type: EXPERIMENTAL
Intervention: Low-intensity aquatic exercise program for 12 weeks
Number of subjects: 16
Study: 27075924

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 2942

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2942
Study: 25773557

Group type: EXPERIMENTAL
Intervention: Time trade-off (TTO) responses
Number of subjects: 22225

Group type: EXPERIMENTAL
Intervention: Paired comparison responses
Number of subjects: 22225
Study: 23720197

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 364
Study: 20499747

Group type: EXPERIMENTAL
Intervention: Tourniquet group
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-tourniquet group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 18956979

Group type: EXPERIMENTAL
Intervention: HIV risk reduction intervention
Number of subjects: 791

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 791
Study: 16513608

Group type: EXPERIMENTAL
Intervention: 123I‐IMP SPECT
Number of subjects: 19

Group type: COMPARATOR
Intervention: 18F‐FDG PET
Number of subjects: 19
Study: 12661673

Group type: EXPERIMENTAL
Intervention: Aerobic fitness training
Number of subjects: 0
Study: 10759280

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8633409

Group type: EXPERIMENTAL
Intervention: Subcapsular orchiectomy
Number of subjects: 74

Group type: COMPARATOR
Intervention: Total orchiectomy
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 74
Study: 1378689

Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 6476545

Group type: EXPERIMENTAL
Intervention: Automatic external defibrillator (AED)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary resuscitation (CPR) instruction with AED
Number of subjects: 0

Group type: COMPARATOR
Intervention: CPR instruction alone
Number of subjects: 0
Study: 31405706

Group type: EXPERIMENTAL
Intervention: Resveratrol supplementation for 4 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 43
Study: 29159538

Group type: EXPERIMENTAL
Intervention: High-intensity conditions (RPE = 16)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Low-intensity conditions (RPE = 12)
Number of subjects: 7
Study: 27721537

Group type: EXPERIMENTAL
Intervention: Febuxostat (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Allopurinol (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 90
Study: 24276777

Group type: EXPERIMENTAL
Intervention: Nurse navigator support for 4 months
Number of subjects: 251

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 251
Study: 23024023

Group type: EXPERIMENTAL
Intervention: Directly Observed Inhaled Corticosteroid (DOICS) treatment with budesonide 1,600 μg for 7 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Directly Observed Inhaled Corticosteroid (DOICS) treatment with budesonide 1,600 μg for 5 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fe(NO) test for nonadherence
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prospective validation of the Fe(NO) test
Number of subjects: 40
Study: 20304584

Group type: EXPERIMENTAL
Intervention: Iron reduction (phlebotomy)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Statin administration
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ferritin levels
Number of subjects: 100
Study: 17627681

Group type: EXPERIMENTAL
Intervention: i.v. hydralazine (5 mg doses)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: mini‐bolus diazoxide (15 mg doses)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 124
Study: 15954919

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 44

Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 44
Study: 12098159

Group type: EXPERIMENTAL
Intervention: Real low-level laser therapy (LLLT) plus microamperes transcutaneous electric nerve stimulation (TENS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham low-level laser therapy (LLLT) plus microamperes transcutaneous electric nerve stimulation (TENS)
Number of subjects: 11
Study: 10073725

Group type: EXPERIMENTAL
Intervention: ALM + BCG
Number of subjects: 2453

Group type: COMPARATOR
Intervention: BCG
Number of subjects: 2453

Group type: EXPERIMENTAL
Intervention: LST responders on day 80 (> or =5 mm)
Number of subjects: 2453
Study: 7744087

Group type: EXPERIMENTAL
Intervention: Felodipine ER 10 mg o.m.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Nifedipine SR 20 mg b.d.
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 2289097

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural problem solving
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 20
Study: 6271049

Group type: EXPERIMENTAL
Intervention: Cefotaxime (1.0 g) intramuscularly
Number of subjects: 97

Group type: COMPARATOR
Intervention: Procaine penicillin G (4.8 x 10(6) U) intramuscularly with 1 g of probenecid orally
Number of subjects: 97
Study: 30642667

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC)
Number of subjects: 86

Group type: COMPARATOR
Intervention: No oral anticoagulation (non-OAC)
Number of subjects: 86
Study: 28256356

Group type: EXPERIMENTAL
Intervention: 3 weeks of intensive speech and language therapy (≥10 hours per week)
Number of subjects: 158

Group type: COMPARATOR
Intervention: 3 weeks deferral of intensive speech and language therapy
Number of subjects: 158
Study: 26553106

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 0
Study: 24045249

Group type: EXPERIMENTAL
Intervention: 0.03 mmol/kg gadofosveset
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.02 mmol/kg gadofosveset
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.01 mmol/kg gadofosveset
Number of subjects: 30
Study: 21177034

Group type: EXPERIMENTAL
Intervention: 2-minute resistance training
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 12-minute resistance training
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (weekly information on general health)
Number of subjects: 198
Study: 20355166

Group type: EXPERIMENTAL
Intervention: Testosterone (250 mg Sustanon) administered weekly for five weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 17855669

Group type: EXPERIMENTAL
Intervention: High-dose melphalan plus autologous stem cells
Number of subjects: 100

Group type: COMPARATOR
Intervention: Melphalan plus high-dose dexamethasone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-dose melphalan plus autologous stem cells (low-risk disease)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Melphalan plus high-dose dexamethasone (low-risk disease)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-dose melphalan plus autologous stem cells (high-risk disease)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Melphalan plus high-dose dexamethasone (high-risk disease)
Number of subjects: 100
Study: 15649112

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program
Number of subjects: 541
Study: 11552963

Group type: EXPERIMENTAL
Intervention: Mild pH neutral soap and water
Number of subjects: 140

Group type: COMPARATOR
Intervention: Water alone
Number of subjects: 140
Study: 9559773

Group type: EXPERIMENTAL
Intervention: Cefepime (2 g administered every 12 h)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Ceftriaxone (1 g administered every 12 h)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 115

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 115
Study: 7524917

Group type: EXPERIMENTAL
Intervention: Balloon dilation (BDP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transurethral incision of the prostate (TUIP)
Number of subjects: 30
Study: 3665393

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg administered alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg administered concurrently with antacid (62 mL of aluminum and magnesium hydroxide suspension)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg administered with antacid one hour after the ibuprofen dose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg administered concurrently with antacid plus three more antacid doses given every five hours
Number of subjects: 8
Study: 31898090

Group type: EXPERIMENTAL
Intervention: Episodic migraine (EM)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Chronic migraine (CM)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: All patients (EM and CM)
Number of subjects: 56
Study: 29450332

Group type: EXPERIMENTAL
Intervention: Longitudinal ultrasound mode
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Torsional ultrasound mode
Number of subjects: 52
Study: 24299501

Group type: EXPERIMENTAL
Intervention: NEXThaler
Number of subjects: 66
Study: 23542612

Group type: EXPERIMENTAL
Intervention: Topical ketoprofen 50 mg
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Topical ketoprofen 100 mg
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Ketoprofen-free vehicle 2.2 g (TDT 064)
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Ketoprofen-free vehicle 4.4 g (TDT 064)
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Oral celecoxib 100 mg
Number of subjects: 1395

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 1395
Study: 20976815

Group type: EXPERIMENTAL
Intervention: Burch colpopexy or autologous fascial sling
Number of subjects: 655
Study: 18218783

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion 1 (before fingolimod administration)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fingolimod administration
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion 2 (in the presence of fingolimod)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Total isoproterenol dose with fingolimod
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusions 3 to 5
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 14
Study: 16752097

Group type: EXPERIMENTAL
Intervention: Classroom curricula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer leadership
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Youth-driven/led extra-curricular activities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parent involvement programs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community activism
Number of subjects: 0
Study: 12728219

Group type: EXPERIMENTAL
Intervention: Beef-containing diet
Number of subjects: 21

Group type: COMPARATOR
Intervention: Vegetarian diet
Number of subjects: 21
Study: 11701431

Group type: EXPERIMENTAL
Intervention: 25 mg testosterone enanthate
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 50 mg testosterone enanthate
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 125 mg testosterone enanthate
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 300 mg testosterone enanthate
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 600 mg testosterone enanthate
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: GnRH agonist plus graded doses of testosterone
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (GnRH agonist only)
Number of subjects: 61
Study: 9388519

Group type: EXPERIMENTAL
Intervention: RT and daily low dose of CDDP (5 mg/m2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: RT only
Number of subjects: 24
Study: 8198916

Group type: EXPERIMENTAL
Intervention: Thiopentone 5.1 mg kg‐1 with suxamethonium
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Propofol 2.2 mg kg‐1 with suxamethonium
Number of subjects: 43
Study: 2884854

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 96

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 96
Study: 29893222

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 28060585

Group type: EXPERIMENTAL
Intervention: Foreshadowed death narratives
Number of subjects: 635

Group type: COMPARATOR
Intervention: Survivor narratives
Number of subjects: 635

Group type: COMPARATOR
Intervention: Death narratives
Number of subjects: 635
Study: 26677123

Group type: EXPERIMENTAL
Intervention: Retrograde ventricle-sinus shunt (RVSS)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ventricular-peritoneal shunt (VPS)
Number of subjects: 9
Study: 23311877

Group type: EXPERIMENTAL
Intervention: OPTIMA-improved stoves
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control stoves
Number of subjects: 93
Study: 22338818

Group type: EXPERIMENTAL
Intervention: Oral health action plan including child's current caries-risk status, identification of issues of concern, and one goal to improve on for the next visit.
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (details not specified in the abstract).
Number of subjects: 69
Study: 18804362

Group type: EXPERIMENTAL
Intervention: Formoterol 10 microg b.i.d. plus tiotropium 18 microg o.d.
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Formoterol 10 microg b.i.d.
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg o.d.
Number of subjects: 847

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 847
Study: 17122760

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted surgery (LPS)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Open surgery (LPT)
Number of subjects: 610
Study: 12749510

Group type: EXPERIMENTAL
Intervention: Granisetron alone (40 microg/kg i.v.)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Granisetron/dexamethasone combination (40 microg/kg granisetron + 8 mg dexamethasone)
Number of subjects: 120
Study: 10833097

Group type: EXPERIMENTAL
Intervention: Rubber Band Ligation (RBL)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Infra-red Coagulation (IRC)
Number of subjects: 133
Study: 9170120

Group type: EXPERIMENTAL
Intervention: 300 mg micronized progesterone administered in the evening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8466015

Group type: EXPERIMENTAL
Intervention: 5 micrograms/mL norepinephrine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 10 micrograms/mL norepinephrine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 15 micrograms/mL norepinephrine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Plain tetracaine (0 micrograms/mL norepinephrine)
Number of subjects: 80
Study: 31363043

Group type: EXPERIMENTAL
Intervention: Endovascular therapy favored by female physicians under ideal conditions
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Endovascular therapy favored by male physicians under ideal conditions
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Endovascular therapy favored by female physicians under current local resources
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Endovascular therapy favored by male physicians under current local resources
Number of subjects: 607
Study: 31622158

Group type: EXPERIMENTAL
Intervention: β-alanine supplementation (6.4 g/day) during HIIT
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (dextrose) during HIIT
Number of subjects: 18
Study: 28923793

Group type: EXPERIMENTAL
Intervention: 20 million allogeneic human mesenchymal stem cells
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 million allogeneic human mesenchymal stem cells
Number of subjects: 30
Study: 26162514

Group type: EXPERIMENTAL
Intervention: Tourniquet group
Number of subjects: 70

Group type: COMPARATOR
Intervention: Non-tourniquet group
Number of subjects: 70
Study: 25445808

Group type: EXPERIMENTAL
Intervention: Complete program (Saluda)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Program minus public commitment
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Program minus resistance to advertising
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Program minus leisure promotion
Number of subjects: 480

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 480
Study: 21946853

Group type: EXPERIMENTAL
Intervention: Ischaemic anaesthesia with wrist and fingers held straight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ischaemic anaesthesia with wrist and fingers flexed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ischaemic anaesthesia
Number of subjects: 0
Study: 18989245

Group type: EXPERIMENTAL
Intervention: h‐ANP (human atrial natriuretic peptide) treatment, 0.02 microg/kg/min for 5 days or more
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: h‐ANP treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: non‐h‐ANP treatment (Group N)
Number of subjects: 18
Study: 16433401

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT/NRC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: One Up Bond F
Number of subjects: 30
Study: 12577195

Group type: EXPERIMENTAL
Intervention: Trizivir (zidovudine, lamivudine, abacavir)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Continued HAART
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Trizivir
Number of subjects: 209